RSPH vs. CNCR

Last updated Jun 4, 2026

RSPH (Invesco S&P 500 Equal Weight Health Care ETF) and CNCR (Loncar Cancer Immunotherapy ETF) are both Health & Biotech Equities funds - RSPH tracks the S&P 500 Equal Weighted / Health Care -SEC while CNCR tracks the Loncar Cancer Immunotherapy Index. Both are passively managed. RSPH charges 0.40%/yr vs 0.79%/yr for CNCR.

Performance

RSPH vs. CNCR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Invesco S&P 500 Equal Weight Health Care ETF (RSPH) and Loncar Cancer Immunotherapy ETF (CNCR). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

RSPH

• 1D: 0.81%
• 1M: 2.49%
• YTD: -2.71%
• 6M: -2.70%
• 1Y: 8.70%
• 3Y*: 3.21%
• 5Y*: 2.54%
• 10Y*: 7.94%

CNCR

• 1D: 0.00%
• 1M: 0.00%
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

RSPH vs. CNCR - Yearly Performance Comparison

	2026 (YTD)
RSPH Invesco S&P 500 Equal Weight Health Care ETF	-5.21%
CNCR Loncar Cancer Immunotherapy ETF	0.00%

RSPH vs. CNCR - Sectors Allocation Comparison

Sectors	RSPH	CNCR
Healthcare	98.5%	96.6%
Financial Services	0.1%	3.3%
Basic Materials	-	-
Communication Services	-	-
Consumer Cyclical	-	-
Consumer Defensive	-	-
Energy	-	-
Industrials	-	-
Real Estate	-	-
Technology	-	-
Utilities	-	-

Return for Risk

RSPH vs. CNCR — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

RSPH

RSPH Risk / Return Rank: 18
RSPH Sharpe Ratio Rank: 18
RSPH Sortino Ratio Rank: 18
RSPH Omega Ratio Rank: 17
RSPH Calmar Ratio Rank: 19
RSPH Martin Ratio Rank: 19

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

RSPH vs. CNCR - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Invesco S&P 500 Equal Weight Health Care ETF (RSPH) and Loncar Cancer Immunotherapy ETF (CNCR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	RSPH	CNCR	Difference
Sharpe ratio Return per unit of total volatility	0.57	—	—
Sortino ratio Return per unit of downside risk	0.91	—	—
Omega ratio Gain probability vs. loss probability	1.11	—	—
Calmar ratio Return relative to maximum drawdown	0.80	—	—
Martin ratio Return relative to average drawdown	2.01	—	—
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

Sharpe Ratios by Period

	RSPH	CNCR	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.57	—	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.16	—	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.45	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.58	—	—

Drawdowns

RSPH vs. CNCR - Drawdown Comparison

The maximum RSPH drawdown since its inception was -40.49%, which is greater than CNCR's maximum drawdown of 0.00%. Use the drawdown chart below to compare losses from any high point for RSPH and CNCR.

Drawdown Indicators

	RSPH	CNCR	Difference
Max Drawdown Largest peak-to-trough decline	-40.49%	0.00%	-40.49%
Max Drawdown (1Y) Largest decline over 1 year	-10.87%	—	—
Max Drawdown (3Y) Largest decline over 3 years	-17.13%	—	—
Max Drawdown (5Y) Largest decline over 5 years	-21.95%	—	—
Max Drawdown (10Y) Largest decline over 10 years	-30.44%	—	—
Current Drawdown Current decline from peak	-6.83%	0.00%	-6.83%
Average Drawdown Average peak-to-trough decline	-6.14%	0.00%	-6.14%
Ulcer Index Depth and duration of drawdowns from previous peaks	4.33%	—	—

Volatility

Volatility by Period

	RSPH	CNCR	Difference
Volatility (1M) Calculated over the trailing 1-month period	3.87%	—	—
Volatility (6M) Calculated over the trailing 6-month period	10.36%	—	—
Volatility (1Y) Calculated over the trailing 1-year period	15.46%	0.00%	+15.46%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	16.26%	0.00%	+16.26%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	17.72%	0.00%	+17.72%

RSPH vs. CNCR - Expense Ratio Comparison

RSPH has a 0.40% expense ratio, which is lower than CNCR's 0.79% expense ratio.

Dividends

RSPH vs. CNCR - Dividend Comparison

RSPH's dividend yield for the trailing twelve months is around 0.73%, while CNCR has not paid dividends to shareholders.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
CNCR Loncar Cancer Immunotherapy ETF	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
RSPH Invesco S&P 500 Equal Weight Health Care ETF	0.73%	0.70%	0.71%	0.66%	0.64%	0.50%	0.51%	0.54%	0.53%	0.47%	0.48%	0.49%

Frequently Asked Questions

Which ETF is better, RSPH or CNCR?

On fees, RSPH is cheaper at 0.40% per year. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF is cheaper, RSPH or CNCR?

RSPH is cheaper with a 0.40% expense ratio, compared with 0.79% for CNCR.

Which ETF pays a higher dividend yield, RSPH or CNCR?

RSPH has the higher dividend yield at 0.73%, compared with 0.00% for CNCR.

What is the main difference between RSPH and CNCR?

RSPH tracks S&P 500 Equal Weighted / Health Care -SEC, while CNCR tracks Loncar Cancer Immunotherapy Index. They also come from different issuers: Invesco and Exchange Traded Concepts. Their fees differ too: 0.40% for RSPH and 0.79% for CNCR.